In many diseases, such as Parkinson’s disease, the mitochondria are damaged. In these cases, key proteins responsible for maintaining mitochondrial health (such as ubiquitin E3 ligases) may have mutations that make the enzyme non-functional. Genetic testing will allow us to determine if you have any DNA mutations/variants that can potentially put your mitochondrial health at risk. If so, you may be predisposed to Parkinson’s disease or other neurogenerative disorders. Myto Health will establish a data bank to store confidential DNA sequencing data E3 ligases. Variant of E3 ligase will be used to express and purify mutated ligase or variant. Biochemical activity of the mutated ligase will be correlated with structural model of the proteins. This knowledge about the structure and function of the ligase will not only help design better PD drugs but also act as a repository to build an artificial intelligence model to interrogate human variants of the ubiquitin ligase and predict pre-disposition to PD. Thus, genetic screening gives a personalized insight into your health, allowing you to make better medical decisions and act more effectively.